Search Results
Jun 03, 2026, 08:00 ET IDefine and UT Southwestern Announce Research Collaboration to Advance Gene Therapy for Rare Disease Kleefstra Syndrome
- Dr. Steven Gray will lead research effort focused on potential therapy to replace the EHMT1 gene in patients with rare neurodevelopmental disorderATLANTA, June 3, 2026 /PRNewswire/ -- IDefine – The Kleefstra
More news about: IDefine - The Kleefstra Syndrome Foundation
Jun 03, 2026, 08:00 ET Altimeter Solutions Group Names Keith Hemmer Chief Operating Officer
foundation and client-first culture that define Altimeter today," said Jonathan Miko, Chief Executive Officer of Altimeter Solutions Group. "He brings a rare combination of industry expertise, strategic perspective, and steady leadership. As we continue to grow and evolve our platform, Keith's ability to
More news about: Altimeter Solutions Group
Jun 03, 2026, 08:00 ET Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.We are committed to fighting stigma and we act to improve health equity. We strive to
More news about: Cradle
Jun 03, 2026, 08:00 ET Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.We are committed to fighting stigma and we act to improve health equity. We strive to
More news about: Cradle
Jun 03, 2026, 03:15 ET BenQ at COMPUTEX 2026: Advancing AI Transformation Through Specialized Experiences and Human-Centric Innovation
performance.Inside BenQ's R&D Labs: Where Engineering Meets Human InsightBenQ has opened its headquarters R&D labs to global audiences, offering a rare look into the science behind its product DNA. The labs demonstrate how BenQ integrates optical engineering, human factors research, biomechanics, and
More news about: BenQ Corporation
Jun 03, 2026, 02:00 ET Quobly lève 115 millions d'euros en Série A pour commercialiser ses ordinateurs quantiques sur silicium
industrielles et critiques. »Philippe Delmas, Président du conseil d'administration, Quobly« Quobly réunit une combinaison rare entre excellence scientifique de rupture et discipline d'exécution industrielle. L'entreprise se positionne à l'intersection de trois domaines stratégiques
More news about: Quobly
Jun 03, 2026, 01:30 ET Factorial Raises $150M Series D, Reaches $2.5 Billion Valuation to Become One of the Most Valuable AI Scale-Ups in Europe
the ones that bolt it on. Factorial is doing exactly that, and doing it with a level of product horizontality and an ambitious growth at scale that is rare anywhere in the world. That combination is why we are deepening our partnership across both equity and our Customer Value Fund.""At General
More news about: Team Lewis Barcelona
Jun 03, 2026, 01:30 ET Factorial Raises $150M Series D, Reaches $2.5 Billion Valuation to Become One of the Most Valuable AI Scale-Ups in Europe
the ones that bolt it on. Factorial is doing exactly that, and doing it with a level of product horizontality and an ambitious growth at scale that is rare anywhere in the world. That combination is why we are deepening our partnership across both equity and our Customer Value Fund.""At General
More news about: Team Lewis Barcelona
Jun 03, 2026, 01:30 ET Factorial lève 150 M$ en série D et atteint une valorisation de 2,5 milliards de dollars pour devenir l'une des scale-ups IA les mieux valorisées en Europe
qui se reconstruisent autour de l'IA, pas à celles qui s'y contentent d'ajouter des fonctionnalités. Factorial fait exactement cela, avec un niveau rare d'horizontalité produit et une ambition de croissance à grande échelle. C'est pourquoi nous renforçons notre partenariat, à la fois via l'investissement
More news about: Team Lewis Barcelona
Jun 03, 2026, 01:03 ET Ajay Rajan joins Protean eGov Technologies Ltd. as Managing Director & Chief Executive Officer
scale. As the company enters its next phase of growth and innovation, we are pleased to welcome Ajay Rajan as Managing Director & CEO. Ajay brings a rare combination of institutional leadership, deep understanding of digital ecosystems, and strong execution experience across banking and technology. We
More news about: Protean eGov Technologies Limted
Jun 03, 2026, 01:00 ET Quobly secures €115 million Series A to bring silicon-based quantum computers to market
systems for industrial and critical applications."Philippe Delmas, Chairman of the Board, Quobly "Quobly represents a rare combination of breakthrough scientific capability and industrial execution discipline. The company is positioning itself at the intersection of quantum
More news about: Quobly
Jun 03, 2026, 01:00 ET Quobly secures €115 million Series A to bring silicon-based quantum computers to market
systems for industrial and critical applications."Philippe Delmas, Chairman of the Board, Quobly "Quobly represents a rare combination of breakthrough scientific capability and industrial execution discipline. The company is positioning itself at the intersection of quantum
More news about: Quobly
Jun 03, 2026, 00:04 ET Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
functions.2,3 Nipocalimab is being investigated across three key segments in the autoantibody space including Rheumatologic disease, Rare Autoantibody diseases and Maternal Fetal diseases mediated by maternal alloantibodies in which blockade of IgG binding to FcRn in the placenta is also
More news about: Johnson & Johnson
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
immune functions.13,14 Nipocalimab is being investigated across three key segments in the autoantibody space including Rheumatologic diseases, Rare Autoantibody diseases andMaternal Fetal diseases mediated by maternal alloantibodies in which blockade of IgG binding to FcRn in the placenta is also
More news about: Johnson & Johnson
Jun 02, 2026, 21:20 ET Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their value in a single session.NEW YORK, June
More news about: SueWallSt.com
Jun 02, 2026, 20:55 ET Young Explorers Invited to Discover Nature During Community BioBlitz at Muscle Shoals Reservation Trails
leaders is to get them outside experiencing nature firsthand," said Julie Graham, TRV Stewardship Council spokesperson. "Whether a child discovers a rare wildflower, spots a bird they've never seen before, or simply develops a new appreciation for the outdoors, those experiences can spark a lifelong passion
More news about: TRV Stewardship Council
Jun 02, 2026, 16:11 ET HILCO GLOBAL ANNOUNCES JUNE 26 AS DEADLINE TO SUBMIT BIDS FOR THE HAWTHORNE RACE COURSE
operations at Hilco Global. "With exceptional multi-modal logistics connectivity and strong surrounding market fundamentals, Hawthorne represents a truly rare opportunity to reimagine a landmark asset for its next chapter. Regardless of its future use, this sale is a once-in-a-generation chance to shape one
More news about: Hilco Trading, LLC
Jun 02, 2026, 15:30 ET Skyhawk Therapeutics annonce les résultats intermédiaires à douze mois de l'essai clinique de phases 1/2 de SKY-0515 dans le traitement de la maladie de Huntington
offertes par la plateforme de petites molécules de Skyhawk sont porteuses d'espoir. »La maladie de Huntington est une maladie neurodégénérative rare, héréditaire et finalement mortelle qui touche plus de 40 000 personnes symptomatiques aux États-Unis et des centaines de milliers dans le monde entier.
More news about: Skyhawk Therapeutics
Jun 02, 2026, 13:00 ET Scott Palladino Joins Trucordia in SVP, Head of Insurance Markets and Broking Role
Development at Clear Blue Insurance Group, where he played a key role in growing the company to $1.5 billion in gross written premium."Scott brings a rare combination of underwriting depth, market perspective, and platform-building experience," said Felix Morgan, CEO of Trucordia. "He understands the mechanics
More news about: Trucordia
Jun 02, 2026, 12:49 ET Statement of Acting Chairman Peter A. Feldman on the Nomination of Brien Lorenze to the Consumer Product Safety Commission
of significant modernization while maintaining a steadfast commitment to our core mission of protecting American consumers.Brien possesses a rare combination of policy expertise, operational acumen, and sound judgment. He understands the Commission's work from the ground up, values the contributions
More news about: U.S. Consumer Product Safety Commission
Jun 02, 2026, 12:31 ET TYKO CAPITAL PROVIDES $870 MILLION CONSTRUCTION LOAN FOR FOUR SEASONS PRIVATE RESIDENCES LAKE AUSTIN
protected land, the community spans 210 acres and nearly a mile of Lake Austin shoreline. Approximately 20 minutes from downtown, the location offers a rare combination of seclusion and accessibility.The project offers an extraordinary collection of resort-style amenities, highlighted by The Upper
More news about: Four Seasons Private Residences Lake Austin
Jun 02, 2026, 11:37 ET Society Awards Selected as an Official Licensed Producer of America250 Commemorative Medals
America250 commemorative medals by Society Awards are part of the official licensed America250 merchandise program, offering collectors and institutions a rare opportunity to acquire high-end, die-struck medals marking the 250th anniversary of the United States. As large-format, solid brass commemorative medals,
More news about: Society Awards
Jun 02, 2026, 11:30 ET Where Forensic Science Meets AI: eSleuth, Inc. Names Former ATF Director Ken Melson to Its Advisory Board
appointment of Kenneth E. Melson, former Acting Director of the Bureau of Alcohol, Tobacco, Firearms and Explosives, to its Advisory Board. Melson brings a rare depth of expertise spanning federal prosecution, agency leadership, and forensic science policy that directly strengthens eSleuth AI's mission to transform
More news about: eSleuth AI
Jun 02, 2026, 11:15 ET Injectable Drug Delivery Market Size to Grow from US$655.1 Billion in 2026 to US$1182.2 Billion by 2033 | Persistence Market Research
encouraging this transition to reduce hospitalization costs and improve patient convenience. Biologic therapies for autoimmune disorders, diabetes, and rare diseases are increasingly being designed for self-injection, allowing patients to manage treatment schedules independently.The wearable injector
More news about: Persistence Market Research Pvt. Ltd.
Jun 02, 2026, 11:00 ET Docusign Appoints Graham Sheldon as Chief Product Officer to Accelerate Intelligent Agreement Management Vision
led product and engineering initiatives across Dynamics, Bing, and Office, giving him a rare, enterprise-wide perspective on how technology transforms organizations at scale."Docusign has achieved something rare in the technology industry: the deep, lasting trust of the world's largest enterprises,"
More news about: Docusign, Inc.